A Phase 1b Study of Sevacizumab in Combination With Chemotherapy in Chinese Patients With Platinum-Resistant Recurrent Ovarian Cancer.

NCT03763123 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: Sevacizumab
DRUG: Paclitaxel
DRUG: Topotecan

Sponsor

Jiangsu Simcere Pharmaceutical Co., Ltd.